Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage.

Preininger A, Schlokat U, Mohr G, Himmelspach M, Stichler V, Kyd-Rebenburg A, Plaimauer B, Turecek PL, Schwarz HP, Wernhart W, Fischer BE, Dorner F.

Cytotechnology. 1999 Jul;30(1-3):1-16. doi: 10.1023/A:1008030407679.

2.

Reduced tabletability of roller compacted granules as a result of granule size enlargement.

Sun CC, Himmelspach MW.

J Pharm Sci. 2006 Jan;95(1):200-6.

PMID:
16315244
3.

A fully recombinant partial prothrombin complex effectively bypasses fVIII in vitro and in vivo.

Himmelspach M, Richter G, Muhr E, Varadi K, Turecek PL, Dorner F, Schwarz HP, Schlokat U.

Thromb Haemost. 2002 Dec;88(6):1003-11.

PMID:
12529752
4.

'Shed' furin: mapping of the cleavage determinants and identification of its C-terminus.

Plaimauer B, Mohr G, Wernhart W, Himmelspach M, Dorner F, Schlokat U.

Biochem J. 2001 Mar 15;354(Pt 3):689-95.

5.

Recombinant human factor X: high yield expression and the role of furin in proteolytic maturation in vivo and in vitro.

Himmelspach M, Pfleiderer M, Fischer BE, Plaimauer B, Antoine G, Falkner FG, Dorner F, Schlokat U.

Thromb Res. 2000 Jan 15;97(2):51-67.

PMID:
10688334
6.

Binding of hirudin to meizothrombin.

Fischer BE, Schlokat U, Himmelspach M, Dorner F.

Protein Eng. 1998 Aug;11(8):715-21.

PMID:
9749925
7.
8.

Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by furin-mediated propeptide removal in vitro.

Schlokat U, Fischer BE, Herlitschka S, Antoine G, Preininger A, Mohr G, Himmelspach M, Kistner O, Falkner FG, Dorner F.

Biotechnol Appl Biochem. 1996 Dec;24(3):257-67.

PMID:
8969456
9.

Specific quantitation of genomic DNA in the femtogram range by amplification of repetitive sequences.

Himmelspach M, Gruber F, Antoine G, Falkner FG, Dorner F, Hämmerle T.

Anal Biochem. 1996 Nov 15;242(2):240-7.

PMID:
8937568
10.

Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A.

Bevec D, Jaksche H, Oft M, Wöhl T, Himmelspach M, Pacher A, Schebesta M, Koettnitz K, Dobrovnik M, Csonga R, Lottspeich F, Hauber J.

Science. 1996 Mar 29;271(5257):1858-60.

PMID:
8596953
11.
12.

Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation.

Ruhl M, Himmelspach M, Bahr GM, Hammerschmid F, Jaksche H, Wolff B, Aschauer H, Farrington GK, Probst H, Bevec D, et al.

J Cell Biol. 1993 Dec;123(6 Pt 1):1309-20.

13.

Modulation of alternative splicing of adenoviral E1A transcripts: factors involved in the early-to-late transition.

Gattoni R, Chebli K, Himmelspach M, Stévenin J.

Genes Dev. 1991 Oct;5(10):1847-58.

Supplemental Content

Loading ...
Support Center